Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 186 participants.

Also called NCT01384747

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 186 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01384747
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01384747. Randomized; triple masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2018-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)
Intervention (Drug)
Fimasartan
Intervention (Drug)
Placebo
Lead sponsor
Seung-Jung Park (class: other)
Collaborator
CardioVascular Research Foundation, Korea (class: other)
Collaborator
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct01384747
Content hash
6cf2f7d57820b0baee5f9934173b35aab173cf49051eeabb0dd07deba9e8fb50